NGL Fine-Chem Reports Q1 Revenue of ₹1.39 Billion

MUMBAI, India — NGL Fine-Chem Limited reported a sharp rise in its quarterly financial performance for the period ended June 30, 2026, recording consolidated revenue from operations of ₹1.39 billion (₹13,916.28 lakhs).

The Mumbai-headquartered active pharmaceutical ingredient (API) manufacturer posted a consolidated net profit from continuing operations of ₹184 million (₹1,839.72 lakhs) for the first quarter of the financial year 2026–27.

Operational Performance and Financial Breakdown

According to regulatory filings submitted to the BSE Limited and the National Stock Exchange of India Limited, NGL Fine-Chem generated total consolidated revenue of ₹1.47 billion (₹14,659.09 lakhs) during the April–June quarter. This includes other income amounting to ₹74.28 million (₹742.81 lakhs).

In comparison, the company achieved total expenses of ₹1.22 billion (₹12,211.42 lakhs) for the quarter. Cost of materials consumed accounted for ₹804.74 million, while employee benefit expenses reached ₹189.18 million. Depreciation and amortization expenses were reported at ₹52.54 million, with finance costs standing at ₹9.85 million. Profit before tax for the consolidated entity stood at ₹244.77 million (₹2,447.68 lakhs).

On a standalone basis, NGL Fine-Chem reported revenue from operations of ₹1.37 billion (₹13,671.32 lakhs) and a net profit from continuing operations of ₹164.51 million (₹1,645.13 lakhs). Basic earnings per share (EPS) for the consolidated group rose to ₹29.78 for the quarter, up from ₹14.96 in the corresponding quarter of the previous year.

Regulatory Clearances and Corporate Governance

The financial results were reviewed by the Audit Committee and subsequently approved by the Board of Directors during its meeting held in Mumbai on August 12, 2026. The board meeting commenced at 4:50 PM IST and concluded at 5:20 PM IST.

Statutory auditors Manek & Associates conducted a limited review of both standalone and consolidated financial statements. The review confirmed that the statements comply with Indian Accounting Standard 34 (Ind AS 34) under Section 133 of the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The auditor issued an unmodified review report.

The consolidated results include the complete financial performance of Macrotech Polychem Private Limited, a wholly-owned subsidiary of NGL Fine-Chem Limited. The group continues to operate within a single business segment, specializing in pharmaceuticals and API manufacturing.

Official Sources Section

Information in this report is sourced directly from statutory filings submitted by NGL Fine-Chem Limited to the BSE Limited and National Stock Exchange of India Limited on August 12, 2026.

Quote Section

According to official filings signed by Managing Director Rahul Nachane, the Board of Directors approved the un-audited consolidated and standalone financial results for the quarter ended June 30, 2026, during its meeting on Wednesday, August 12, 2026.

Organizers stated that the statutory auditors completed a limited review of the results for NGL Fine-Chem Limited and its wholly-owned subsidiary, Macrotech Polychem Private Limited, without raising any material misstatement concerns.

Why It Matters

The first-quarter results provide insight into the manufacturing efficiency and demand recovery in the veterinary and human active pharmaceutical ingredient (API) sectors. For investors, market analysts, and chemical industry suppliers, NGL Fine-Chem's top-line expansion and lower relative finance costs highlight stable operational momentum across domestic and global healthcare supply chains.

Key Facts at a Glance

• Consolidated Revenue from Operations: ₹1.39 billion (₹13,916.28 lakhs).

• Consolidated Net Profit (Continuing Operations): ₹184 million (₹1,839.72 lakhs).

• Consolidated Profit Before Tax (PBT): ₹244.77 million (₹2,447.68 lakhs).

• Consolidated Basic EPS: ₹29.78 per share (Face Value ₹5).

• Subsidiary Included: Macrotech Polychem Private Limited (100% owned).

Frequently Asked Questions (FAQ)

What was NGL Fine-Chem's consolidated revenue in Q1 FY27?

NGL Fine-Chem posted consolidated revenue from operations of ₹1.39 billion (₹13,916.28 lakhs) for the quarter ended June 30, 2026.

How much net profit did NGL Fine-Chem achieve in the June quarter?

The company recorded a consolidated net profit from continuing operations of ₹184 million (₹1,839.72 lakhs).

What was the standalone profit for NGL Fine-Chem in Q1?

On a standalone basis, NGL Fine-Chem generated a net profit of ₹164.51 million (₹1,645.13 lakhs) on revenue of ₹1.37 billion.

Who are the statutory auditors for NGL Fine-Chem?

Chartered accounting firm Manek & Associates served as the statutory auditors for the Q1 financial review.

Sources: NGL Fine-Chem Limited Regulatory Filings, BSE Limited Corporate Announcements, National Stock Exchange of India Limited Filings